Global Vector-Based RNAi Market Research Report 2021

1 Vector-Based RNAi Market Overview

• 1.1 Product Overview and Scope of Vector-Based RNAi
• 1.2 Vector-Based RNAi Segment by Type
  • 1.2.1 Global Vector-Based RNAi Sales Growth Rate Comparison by Type (2021-2027)
  • 1.2.2 siRNA Design
  • 1.2.3 siRNA Vectors
  • 1.2.4 Custom siRNA Construction
• 1.3 Vector-Based RNAi Segment by Application
  • 1.3.1 Vector-Based RNAi Sales Comparison by Application: (2021-2027)
  • 1.3.2 Hospitals
  • 1.3.3 Speciality Clinics
• 1.4 Global Vector-Based RNAi Market Size Estimates and Forecasts
  • 1.4.1 Global Vector-Based RNAi Revenue 2016-2027
  • 1.4.2 Global Vector-Based RNAi Sales 2016-2027
  • 1.4.3 Vector-Based RNAi Market Size by Region: 2016 Versus 2021 Versus 2027

2 Vector-Based RNAi Market Competition by Manufacturers

• 2.1 Global Vector-Based RNAi Sales Market Share by Manufacturers (2016-2021)
• 2.2 Global Vector-Based RNAi Revenue Market Share by Manufacturers (2016-2021)
• 2.3 Global Vector-Based RNAi Average Price by Manufacturers (2016-2021)
• 2.4 Manufacturers Vector-Based RNAi Manufacturing Sites, Area Served, Product Type
• 2.5 Vector-Based RNAi Market Competitive Situation and Trends
  • 2.5.1 Vector-Based RNAi Market Concentration Rate
  • 2.5.2 The Global Top 5 and Top 10 Largest Vector-Based RNAi Players Market Share by Revenue
  • 2.5.3 Global Vector-Based RNAi Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Vector-Based RNAi Retrospective Market Scenario by Region

• 3.1 Global Vector-Based RNAi Retrospective Market Scenario in Revenue by Region: 2016-2021
• 3.2 Global Vector-Based RNAi Retrospective Market Scenario in Sales by Region: 2016-2021
• 3.3 North America Vector-Based RNAi Market Facts & Figures by Country
  • 3.3.1 North America Vector-Based RNAi Sales by Country
  • 3.3.2 North America Vector-Based RNAi Revenue by Country
  • 3.3.3 U.S.
  • 3.3.4 Canada
• 3.4 Europe Vector-Based RNAi Market Facts & Figures by Country
  • 3.4.1 Europe Vector-Based RNAi Sales by Country
  • 3.4.2 Europe Vector-Based RNAi Revenue by Country
  • 3.4.3 Germany
  • 3.4.4 France
  • 3.4.5 U.K.
  • 3.4.6 Italy
  • 3.4.7 Russia
• 3.5 Asia Pacific Vector-Based RNAi Market Facts & Figures by Region
  • 3.5.1 Asia Pacific Vector-Based RNAi Sales by Region
  • 3.5.2 Asia Pacific Vector-Based RNAi Revenue by Region
  • 3.5.3 China
  • 3.5.4 Japan
  • 3.5.5 South Korea
  • 3.5.6 India
  • 3.5.7 Australia
  • 3.5.8 Taiwan
  • 3.5.9 Indonesia
  • 3.5.10 Thailand
  • 3.5.11 Malaysia
  • 3.5.12 Philippines
  • 3.5.13 Vietnam
• 3.6 Latin America Vector-Based RNAi Market Facts & Figures by Country
  • 3.6.1 Latin America Vector-Based RNAi Sales by Country
  • 3.6.2 Latin America Vector-Based RNAi Revenue by Country
  • 3.6.3 Mexico
  • 3.6.4 Brazil
  • 3.6.5 Argentina
• 3.7 Middle East and Africa Vector-Based RNAi Market Facts & Figures by Country
  • 3.7.1 Middle East and Africa Vector-Based RNAi Sales by Country
  • 3.7.2 Middle East and Africa Vector-Based RNAi Revenue by Country
  • 3.7.3 Turkey
  • 3.7.4 Saudi Arabia
  • 3.7.5 UAE

4 Global Vector-Based RNAi Historic Market Analysis by Type

• 4.1 Global Vector-Based RNAi Sales Market Share by Type (2016-2021)
• 4.2 Global Vector-Based RNAi Revenue Market Share by Type (2016-2021)
• 4.3 Global Vector-Based RNAi Price by Type (2016-2021)

5 Global Vector-Based RNAi Historic Market Analysis by Application

• 5.1 Global Vector-Based RNAi Sales Market Share by Application (2016-2021)
• 5.2 Global Vector-Based RNAi Revenue Market Share by Application (2016-2021)
• 5.3 Global Vector-Based RNAi Price by Application (2016-2021)

6 Key Companies Profiled

• 6.1 Merck & Co.
  • 6.1.1 Merck & Co. Corporation Information
  • 6.1.2 Merck & Co. Description and Business Overview
  • 6.1.3 Merck & Co. Vector-Based RNAi Sales, Revenue and Gross Margin (2016-2021)
  • 6.1.4 Merck & Co. Product Portfolio
  • 6.1.5 Merck & Co. Recent Developments/Updates
• 6.2 Phio Pharmaceutical
  • 6.2.1 Phio Pharmaceutical Corporation Information
  • 6.2.2 Phio Pharmaceutical Description and Business Overview
  • 6.2.3 Phio Pharmaceutical Vector-Based RNAi Sales, Revenue and Gross Margin (2016-2021)
  • 6.2.4 Phio Pharmaceutical Product Portfolio
  • 6.2.5 Phio Pharmaceutical Recent Developments/Updates
• 6.3 Quark Pharmaceuticals
  • 6.3.1 Quark Pharmaceuticals Corporation Information
  • 6.3.2 Quark Pharmaceuticals Description and Business Overview
  • 6.3.3 Quark Pharmaceuticals Vector-Based RNAi Sales, Revenue and Gross Margin (2016-2021)
  • 6.3.4 Quark Pharmaceuticals Product Portfolio
  • 6.3.5 Quark Pharmaceuticals Recent Developments/Updates
• 6.4 Thermo Fisher Scientific
  • 6.4.1 Thermo Fisher Scientific Corporation Information
  • 6.4.2 Thermo Fisher Scientific Description and Business Overview
  • 6.4.3 Thermo Fisher Scientific Vector-Based RNAi Sales, Revenue and Gross Margin (2016-2021)
  • 6.4.4 Thermo Fisher Scientific Product Portfolio
  • 6.4.5 Thermo Fisher Scientific Recent Developments/Updates
• 6.5 Silence Therapeutics
  • 6.5.1 Silence Therapeutics Corporation Information
  • 6.5.2 Silence Therapeutics Description and Business Overview
  • 6.5.3 Silence Therapeutics Vector-Based RNAi Sales, Revenue and Gross Margin (2016-2021)
  • 6.5.4 Silence Therapeutics Product Portfolio
  • 6.5.5 Silence Therapeutics Recent Developments/Updates
• 6.6 Qiagen NV
  • 6.6.1 Qiagen NV Corporation Information
  • 6.6.2 Qiagen NV Description and Business Overview
  • 6.6.3 Qiagen NV Vector-Based RNAi Sales, Revenue and Gross Margin (2016-2021)
  • 6.6.4 Qiagen NV Product Portfolio
  • 6.6.5 Qiagen NV Recent Developments/Updates
• 6.7 Ionis Pharmaceutical
  • 6.6.1 Ionis Pharmaceutical Corporation Information
  • 6.6.2 Ionis Pharmaceutical Description and Business Overview
  • 6.6.3 Ionis Pharmaceutical Vector-Based RNAi Sales, Revenue and Gross Margin (2016-2021)
  • 6.4.4 Ionis Pharmaceutical Product Portfolio
  • 6.7.5 Ionis Pharmaceutical Recent Developments/Updates
• 6.8 Dicerna Pharmaceuticals
  • 6.8.1 Dicerna Pharmaceuticals Corporation Information
  • 6.8.2 Dicerna Pharmaceuticals Description and Business Overview
  • 6.8.3 Dicerna Pharmaceuticals Vector-Based RNAi Sales, Revenue and Gross Margin (2016-2021)
  • 6.8.4 Dicerna Pharmaceuticals Product Portfolio
  • 6.8.5 Dicerna Pharmaceuticals Recent Developments/Updates
• 6.9 Arrowhead Pharmaceuticals
  • 6.9.1 Arrowhead Pharmaceuticals Corporation Information
  • 6.9.2 Arrowhead Pharmaceuticals Description and Business Overview
  • 6.9.3 Arrowhead Pharmaceuticals Vector-Based RNAi Sales, Revenue and Gross Margin (2016-2021)
  • 6.9.4 Arrowhead Pharmaceuticals Product Portfolio
  • 6.9.5 Arrowhead Pharmaceuticals Recent Developments/Updates
• 6.10 Arcturus Therapeutics
  • 6.10.1 Arcturus Therapeutics Corporation Information
  • 6.10.2 Arcturus Therapeutics Description and Business Overview
  • 6.10.3 Arcturus Therapeutics Vector-Based RNAi Sales, Revenue and Gross Margin (2016-2021)
  • 6.10.4 Arcturus Therapeutics Product Portfolio
  • 6.10.5 Arcturus Therapeutics Recent Developments/Updates
• 6.11 Alnylam Pharmaceuticals
  • 6.11.1 Alnylam Pharmaceuticals Corporation Information
  • 6.11.2 Alnylam Pharmaceuticals Vector-Based RNAi Description and Business Overview
  • 6.11.3 Alnylam Pharmaceuticals Vector-Based RNAi Sales, Revenue and Gross Margin (2016-2021)
  • 6.11.4 Alnylam Pharmaceuticals Product Portfolio
  • 6.11.5 Alnylam Pharmaceuticals Recent Developments/Updates

7 Vector-Based RNAi Manufacturing Cost Analysis

• 7.1 Vector-Based RNAi Key Raw Materials Analysis
  • 7.1.1 Key Raw Materials
  • 7.1.2 Key Suppliers of Raw Materials
• 7.2 Proportion of Manufacturing Cost Structure
• 7.3 Manufacturing Process Analysis of Vector-Based RNAi
• 7.4 Vector-Based RNAi Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

• 8.1 Marketing Channel
• 8.2 Vector-Based RNAi Distributors List
• 8.3 Vector-Based RNAi Customers

9 Vector-Based RNAi Market Dynamics

• 9.1 Vector-Based RNAi Industry Trends
• 9.2 Vector-Based RNAi Growth Drivers
• 9.3 Vector-Based RNAi Market Challenges
• 9.4 Vector-Based RNAi Market Restraints

10 Global Market Forecast

• 10.1 Vector-Based RNAi Market Estimates and Projections by Type
  • 10.1.1 Global Forecasted Sales of Vector-Based RNAi by Type (2022-2027)
  • 10.1.2 Global Forecasted Revenue of Vector-Based RNAi by Type (2022-2027)
• 10.2 Vector-Based RNAi Market Estimates and Projections by Application
  • 10.2.1 Global Forecasted Sales of Vector-Based RNAi by Application (2022-2027)
  • 10.2.2 Global Forecasted Revenue of Vector-Based RNAi by Application (2022-2027)
• 10.3 Vector-Based RNAi Market Estimates and Projections by Region
  • 10.3.1 Global Forecasted Sales of Vector-Based RNAi by Region (2022-2027)
  • 10.3.2 Global Forecasted Revenue of Vector-Based RNAi by Region (2022-2027)

11 Research Finding and Conclusion

12 Methodology and Data Source

• 12.1 Methodology/Research Approach
  • 12.1.1 Research Programs/Design
  • 12.1.2 Market Size Estimation
  • 12.1.3 Market Breakdown and Data Triangulation
• 12.2 Data Source
  • 12.2.1 Secondary Sources
  • 12.2.2 Primary Sources
• 12.3 Author List